Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 7/20 | 0.53 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.50 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.50 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26516537 | 0.84 | FYN (0.53) | CFTRTLR9TLR8TLR7KCNH2 | |
| SCHEMBL26516610 | 0.81 | TLR8 (0.55) | CFTRTLR9TLR8TLR7MET | |
| SCHEMBL26516612 | 0.76 | MAP4K1 (0.49) | TLR9TLR8TLR7KCNH2 | |
| SCHEMBL30360604 | 0.74 | FYN (0.49) | TLR9TLR8TLR7KCNH2CDK9 | |
| SCHEMBL26516706 | 0.74 | FYN (0.51) | TLR9TLR8TLR7KCNH2CDK9 | |
| SCHEMBL26120751 | 0.74 | FYN (0.49) | TLR9TLR8TLR7KCNH2CDK9 | |
| SCHEMBL30360599 | 0.74 | FYN (0.51) | TLR9TLR8TLR7KCNH2CDK9 | |
| SCHEMBL29006620 | 0.74 | PDGFRB (0.47) | — | |
| SCHEMBL26516625 | 0.73 | TGFBR1 (0.63) | TLR9TLR8TLR7 | |
| SCHEMBL30360632 | 0.70 | MAP4K1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115956077-A | Substituted heteroaryl compounds as TLR9 inhibitors | 百时美施贵宝公司 | 2023-04-11 | — | — | CN | claimed |
| US-20230322770-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322770-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| EP-4200015-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | Bristol-Myers Squibb Company (US) | 2023-06-28 | — | — | EP | disclosed |
| CN-115956077-A | Substituted heteroaryl compounds as TLR9 inhibitors | 百时美施贵宝公司 | 2023-04-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322770-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | TLR9, TLR3, TLR1 | CFTR 52/4885TLR9 1/4885TLR8 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.